Is BPC-157 Legal in 2026?
BPC-157 is currently Category 2 -- restricted from compounding pharmacies. That changes July 23, 2026. Here is the full story, what is legal right now, and what to expect after the PCAC decision.
FDA PCAC Review: July 23, 2026
The FDA Pharmacy Compounding Advisory Committee is scheduled to review BPC-157 on July 23, 2026 for potential reclassification from Category 2 to Category 1. Category 1 would make BPC-157 legally available through 503A compounding pharmacies with a valid prescription.
Official FDA PCAC calendarThe Short Answer
BPC-157 occupies a legal gray zone in 2026. It is not approved by the FDA for human use and cannot currently be prescribed or dispensed by licensed compounding pharmacies. However, it is widely sold as a research chemical -- legal to purchase for laboratory research purposes, but not legally intended for human injection.
This status is expected to change. The FDA PCAC review on July 23, 2026 is specifically examining whether BPC-157 should be moved to Category 1, which would make it available through compounding pharmacies by prescription.
Understanding FDA Category 1 vs Category 2
- •503A compounding pharmacies can produce it
- •Requires valid prescription from licensed physician
- •Pharmaceutical-grade production standards
Examples: Ipamorelin, Sermorelin, GHK-Cu
- •Cannot be compounded by 503A pharmacies
- •Not available by prescription through compounders
- •May still be sold as research chemical
Current status of BPC-157 -- pending PCAC review
BPC-157 Regulatory Timeline
BPC-157 widely available through 503A compounding pharmacies. Prescribed off-label by physicians for wound healing, gut repair, and injury recovery.
FDA placed BPC-157 on the Category 2 list, prohibiting 503A compounding pharmacies from producing it. Research chemical market expands.
HHS Secretary Robert F. Kennedy Jr. directs the FDA to review peptide classifications, specifically targeting BPC-157, TB-500, MOTS-c, KPV, Semax, and Epithalon.
FDA PCAC formally reviews BPC-157 for reclassification. Expected outcome: Category 1.
If reclassified, licensed physicians can prescribe BPC-157 and 503A compounding pharmacies can fill those prescriptions with pharmaceutical-grade product.
How People Currently Access BPC-157
Research Chemical Suppliers Legal gray zone
Sold legally labeled for research use only. No pharmaceutical-grade quality control or required third-party testing.
International Pharmacies Jurisdiction-dependent
Available in some countries. Importing occupies a gray zone under US customs rules.
Post-PCAC: Compounding Pharmacy (Rx) Pending July 23
After Category 1 reclassification, patients with a valid prescription can obtain pharmaceutical-grade BPC-157 from a licensed 503A pharmacy.
Frequently Asked Questions
Is BPC-157 a controlled substance?
No. BPC-157 is not a controlled substance under the DEA Controlled Substances Act. It is restricted from compounding under FDA Category 2 classification -- different from controlled substance scheduling.
Can a doctor prescribe BPC-157 right now?
Not through a US compounding pharmacy. Category 2 status means 503A pharmacies cannot legally prepare it regardless of whether a physician writes a prescription. This is the specific restriction the July 2026 PCAC review is addressing.
What is the quality difference between research chemicals and compounded BPC-157?
Significant. Research chemical suppliers have no required third-party testing for purity, sterility, or dosing accuracy. Compounding pharmacies must meet USP standards and maintain sterile procedures.
When will we know the PCAC review outcome?
The PCAC meets July 23, 2026. The FDA Commissioner then has 60 days to accept, modify, or reject the recommendation. Subscribe to alerts on our Regulatory Status Registry for immediate notification.
Get Notified When the Decision Drops
We will alert you the moment the July 23 PCAC results are announced -- before it hits the news.
References
- [1]Drug Quality and Security Act (DQSA), Section 503A. Pub. L. 113-54. 2013. Governs compounding pharmacies and bulk drug substance nominations.
- [2]U.S. Food & Drug Administration. Pharmacy Compounding Advisory Committee (PCAC). Meeting materials and Federal Register notices. FDA.gov.
- [3]U.S. Food & Drug Administration. 503A Bulks List — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA Drug Policy.
- [4]U.S. Food & Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A. Guidance for Industry. 2019.
Citations are provided for informational context. This article does not reproduce copyrighted content from these sources.
Share this article